AustraliaHealth

Pro Medicus (ASX:PME) has secured two major contract wins in the United States, totalling $44 million.

Paragon Care (ASX:PGC) issued an update regarding its financial exposure to the receivership of the Infinity Retail Pharmacy Group.

PolyNovo (ASX:PNV) has finalised the clinical study report for its US pivotal randomised controlled trial evaluating NovoSorb BTM for full-thickness burns.

4DMedical (ASX:4DX) has secured a commercial agreement with SimonMed Imaging.

Imugene (ASX:IMU) announced a milestone in its ongoing Phase 1b basket study of azer-cel.

Acrux (ASX:ACR) finalised an amendment to its licensing agreement with Gedeon Richter for the transdermal estradiol spray, Lenzetto.

Australian Clinical Labs (ASX:ACL) appointed Greg Horan as its new Group CEO and executive director.

Biome Australia (ASX:BIO) has launched its multi-centre, international clinical trial for BMB18.

Noxopharm (ASX:NOX) shares surge on data showing its proprietary Sofra platform can amplify immune cells to actively fight cancer.

Osteopore (ASX:OSX) secured a major regulatory breakthrough, obtaining approval from the Hainan Medical Products Administration.

Ryman Healthcare (ASX:RYM) achieved its first positive free cash flow in over a decade, reaching NZ$188 million.

Cancer diagnostics company Pacific Edge (ASX:PEB) reported its audited financial results for the 2026 financial year.